Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22321372 | 1.00 | ESR2 (0.47) | ESR2PARP10MLYCDNPC1SCD5 | |
| SCHEMBL1515236 | 0.90 | HTR2C (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL29878889 | 0.90 | HTR2C (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL9196045 | 0.89 | TRPV1 (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL9196040 | 0.89 | TRPV1 (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL7969400 | 0.89 | TRPV1 (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL7969397 | 0.89 | TRPV1 (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL7969391 | 0.89 | TRPV1 (0.47) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL777204 | 0.82 | HDAC4 (0.52) | PARP10MLYCDNPC1SCD5DRD4 | |
| SCHEMBL353609 | 0.82 | HDAC4 (0.47) | PARP10MLYCDNPC1SCD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-10 | — | — | US | disclosed |
| EP-4543432-A1 | SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT | Alkermes, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119730843-A | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment | 阿尔克姆斯有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023249871-A1 | SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249871-A1 | SUBSTITUTED PYRROLIDINYL AND PIPERIDINYL COMPOUNDS AND RELATED METHODS OF TREATMENT | ALKERMES, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11366387-B2 | Salt, acid generator, resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-06-21 | — | — | US | disclosed |
| WO-2022119888-A1 | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
| CN-108884043-B | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2021-11-26 | — | — | CN | disclosed |
| CN-108884043-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | disclosed |
| EP-2279990-B1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2279990-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009145101-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223276-A1 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | HCRTR2, HCRTR1, CNR2 | ESR2 2562/4885PARP10 1291/4885MLYCD 1565/4885 |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK1, ROCK2, LEF1 | ESR2 2984/4885PARP10 2346/4885MLYCD 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.